Free Trial
NASDAQ:MDXH

MDxHealth Q1 2025 Earnings Report

MDxHealth logo
$1.75 +0.03 (+1.74%)
As of 05/5/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDxHealth EPS Results

Actual EPS
N/A
Consensus EPS
-$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

MDxHealth Revenue Results

Actual Revenue
N/A
Expected Revenue
$22.62 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MDxHealth Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

MDxHealth Earnings Headlines

Lake Street Reaffirms Their Buy Rating on MDxHealth (MDXH)
MDxHealth management to meet with Lake Street
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More MDxHealth Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MDxHealth? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MDxHealth and other key companies, straight to your email.

About MDxHealth

MDxHealth (NASDAQ:MDXH), a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

View MDxHealth Profile

More Earnings Resources from MarketBeat